CN110031631A - Stablize, the hoptoglobin detection kit of high specificity - Google Patents
Stablize, the hoptoglobin detection kit of high specificity Download PDFInfo
- Publication number
- CN110031631A CN110031631A CN201910261110.6A CN201910261110A CN110031631A CN 110031631 A CN110031631 A CN 110031631A CN 201910261110 A CN201910261110 A CN 201910261110A CN 110031631 A CN110031631 A CN 110031631A
- Authority
- CN
- China
- Prior art keywords
- reagent
- hoptoglobin
- detection kit
- high specificity
- ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 54
- 239000004615 ingredient Substances 0.000 claims abstract description 16
- 230000006641 stabilisation Effects 0.000 claims abstract description 16
- 238000011105 stabilization Methods 0.000 claims abstract description 16
- 239000000872 buffer Substances 0.000 claims abstract description 8
- 239000004094 surface-active agent Substances 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims abstract description 4
- 230000002335 preservative effect Effects 0.000 claims abstract description 4
- 229910001410 inorganic ion Inorganic materials 0.000 claims abstract description 3
- -1 polyoxyethylene Polymers 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 229920004890 Triton X-100 Polymers 0.000 claims description 2
- 239000013504 Triton X-100 Substances 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims 1
- 244000125380 Terminalia tomentosa Species 0.000 claims 1
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 229940098773 bovine serum albumin Drugs 0.000 abstract 1
- MGIYRDNGCNKGJU-UHFFFAOYSA-N isothiazolinone Chemical compound O=C1C=CSN1 MGIYRDNGCNKGJU-UHFFFAOYSA-N 0.000 abstract 1
- 229920000570 polyether Polymers 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 17
- 102000001554 Hemoglobins Human genes 0.000 description 10
- 108010054147 Hemoglobins Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 102000014702 Haptoglobin Human genes 0.000 description 4
- 108050005077 Haptoglobin Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000218194 Laurales Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a kind of stabilizations, the hoptoglobin detection kit of high specificity, are related to field of biotechnology.The detection kit includes reagent R1 and reagent R2, the ingredient of the reagent R1 is as follows: 10~100mmol/L of buffer, surfactant 1:5~10ml/L, 5~10g/L of inorganic ion, 20~30g/L of accelerator, surfactant 2:2~20g/L, 1~10g/L of isothiazolinone, 0.5~1g/L of preservative；The ingredient and content of the reagent R2 is as follows: 10~100mmol/L of buffer, goat-anti people's hoptoglobin 5~10mg/L of antibody, 5~10g/L of bovine serum albumin, polyethers L-65:0.5~1g/L, D- 10~20g/L of trehalose, 0.5~1g/L of preservative.Strong antijamming capability of the present invention, stability is good and high specificity.
Description
Technical field
The present invention relates to field of biotechnology, and in particular to a kind of stabilization, the hoptoglobin detection reagent of high specificity
Box.
Background technique
Hoptoglobin (Haptoglobin, Hp) is also known as haptoglobin, is a kind of acid sugar egg that molecular weight is 85000
It is white, it is widely present in the serum and other body fluid of the mankind and many mammals, in CAM electrophoresis and agarose gel electrophoresis
In, hoptoglobin is located at 2 zone of α, has two pairs of peptide chains (α chain and β chain) that the tetramer of 2 β 2 of α is collectively formed in molecule.In conjunction with pearl
Albumen is mainly synthesized in liver, is degraded also in liver, half-life period is about 3.5~4 days.
Hp and CRP belongs to acute phase reactive protein, and major function is formed by combining with free hemoglobin (Hb)
Hp-Hb compound, and disposed quickly by the scavenger receptor CD163 that monokaryon-macrophage system mediates, prevent Hb to tissue
Oxidative damage, prevent Hb from glomerular filtration, avoid damage of the Hb to renal tubule.Hp has antioxidant activity, anti-inflammatory, anti-
Bacterium promotes the effects of angiogenesis.
Normal haptoglobin content in serum is in 0.5~2.0g/L, if hoptoglobin level changes, just
It can indicate the generation of disease or the development to anti-disease.Increase and sees gestation, chronic infection etc.；Attenuating sees various molten
Blood, hepatopathy or megaloblastic anemia etc..Protein science has become the new tool of diagnosis diabetic nephropathy.Wherein hoptoglobin
Generation and development with diabetic nephropathy is closely related, therefore its new life that will become prediction diabetes Renal function in early period decline
Substance markers object.
The method of clinical detection hoptoglobin is hemoglobin combined techniques and immunoturbidimetry at present.Wherein, blood red egg
The characteristics of white combined techniques are combined according to hoptoglobin and hemoglobin equimolar, is detected using rocket electrophoresis, i.e., to tested
Excessive hemoglobin is added in serum, the hoptoglobin in serum generates compound in conjunction with hemoglobin, passes through rocket
Two zone of hemoglobin and compound are isolated after electrophoresis, by sequence of operations, calculate the concentration of HP, this method operation step
Rapid complicated and cumbersome, display result speed is slow, error is big, and show the result is that the content of hemoglobin, only reflection indirectly
The content of hoptoglobin clinically fails to carry out extensively.Immunoturbidimetry has operation relative to hemoglobin combined techniques
Simply, the small advantage of testing result error, but the anti-interference energy of existing immunoturbidimetry hoptoglobin detection kit
Power, stability and specificity are poor, also need to be further improved.
Summary of the invention
The present invention provides that a kind of strong antijamming capability, stability is good and the combination pearl of the stabilization of high specificity, high specificity
Protein detection kit.
In order to solve the above technical problems, present invention offer technical solution is as follows:
The present invention provides a kind of stabilization, the hoptoglobin detection kit of high specificity, including reagent R1 and reagent R2,
Wherein:
The ingredient and content of the reagent R1 is as follows:
The ingredient and content of the reagent R2 is as follows:
Further, the ingredient of the reagent R1 and content are as follows:
The ingredient and content of the reagent R2 is as follows:
Further, the buffer is one of PBS buffer solution, glycine buffer, Tris buffer or a variety of
The temperature of combination, the reagent R1 and the buffer in reagent R2 is 25 DEG C, pH value 7.4.
Further, the surfactant 1 is Triton X-100, and the surfactant 2 is polyoxyethylene laural
Ether.
Further, the inorganic ion is one of sodium chloride, potassium chloride, magnesium chloride or multiple combinations.
Further, the accelerator is Polyethylene glycol-2000, polyethylene glycol-6000, one in polyethylene glycol-8 000
Kind or multiple combinations.
Further, the preservative is PC-300.
Further, the ratio of the reagent R1 and reagent R2 is 4:1.
Compared with prior art, the invention has the following advantages:
1) reproducible: the coefficient of variation CV < 5% of hoptoglobin kit of the invention has preferable repeat
Property；
2) stability and anti-interference ability are high: the present invention is using new buffer system and stabilizer and adds a variety of anti-dry
Disturb agent, can the factors such as effectively anti-VC, bilirubin, hemoglobin, triglycerides interference, significantly improve the stability of reagent
And anti-interference；
3) high specificity: goat-anti people's hoptoglobin antibody in hoptoglobin detection kit of the invention can be with
HP specific binding, improves accuracy, easy to use, can satisfy clinical needs completely.
Detailed description of the invention
Fig. 1 is the correlation curve figure of the kit of embodiment 1 and the kit of control group；
Fig. 2 is the correlation curve figure of the kit of embodiment 2 and the kit of control group；
Fig. 3 is the correlation curve figure of the kit of embodiment 3 and the kit of control group；
Fig. 4 is kit treated at the 2-8 DEG C stability curve figure of embodiment 1-3 and control group；
Fig. 5 is kit treated at the 37 DEG C stability curve figure of embodiment 1-3 and control group.
Specific embodiment
To keep the technical problem to be solved in the present invention, technical solution and advantage clearer, below in conjunction with specific implementation
Example and attached drawing are described in detail.
Embodiment 1:
The hoptoglobin detection kit of stabilization, high specificity of the invention includes reagent R1 and reagent R2, in which:
The ingredient and content of the reagent R1 is as follows:
The ingredient and content of the reagent R2 is as follows:
Detection method: automatic clinical chemistry analyzer (such as 7180 fully-automatic analyzer of Hitachi, OLYMPUS AU640 are used
Deng), at dominant wavelength 340nm, it is measured using Two point end assay.Reagent is placed on corresponding reagent position, in sample
The corresponding position of disk places distilled water, calibration object and sample, operation such as table 1:
1 embodiment of table, 1 reagent test method
It calculates: sample haptoglobin content (g/L)=(Δ A measures ÷ Δ A calibration) × C calibration.
Embodiment 2:
The hoptoglobin detection kit of stabilization, high specificity of the invention includes reagent R1 and reagent R2, in which:
The ingredient and content of the reagent R1 is as follows:
The ingredient and content of the reagent R2 is as follows:
Detection method of the detection method with embodiment 1.
Embodiment 3:
The hoptoglobin detection kit of stabilization, high specificity of the invention includes reagent R1 and reagent R2, in which:
The ingredient and content of the reagent R1 is as follows:
The ingredient and content of the reagent R2 is as follows:
Detection method of the detection method with embodiment 1.
The hoptoglobin for certain company that control group is approved using State Food and Drug Administration common in the market
Detection kit.
Repetitive test:
Control test is carried out using the reagent of embodiment 1, embodiment 2, embodiment 3 and control group, detects quality-control product respectively
(target value 1.52g/L) is repeated 10 times, and calculates its coefficient of variation, testing result as shown in table 2
2 kit repeatability testing result of table
As can be seen from Table 7,1,2,3 gained reagent repeatability CV value of above-described embodiment is respectively less than 2%, 1 reagent of embodiment
Repeated CV value only 0.84%, is much better than control group reagent.
Anti-interference test:
Fresh mix serum is taken, 4 equal portions are divided into, every equal portions are then separated into 5 equal portions, different interfering substances is added,
Its concentration in serum is set to reach the requirement of table 3.Then respectively with the knot of embodiment 1, embodiment 2, embodiment 3 and control group
The content of hoptoglobin, measurement result are shown in Table 3 in hop protein detection kit while comparative determination serum.
3 interference test result of table
Relative deviation (%)=(measurement mean value-control group measurement mean value of embodiment)/control group measurement mean value ×
100%.
As can be seen from Table 3,1 reagent of embodiment is in triglycerides≤50mg/dL, bilirubin≤1mg/dL, hemoglobin
Test result is not significantly interfered with when≤50mg/dL, VC≤1mg/dL；Implement the interference free performance of the reagent of 2 and implementation 3 slightly
It is weaker than embodiment 1, but is no more than 5%；And group reagent is compareed in the presence of above-mentioned concentration interfering substance, it is significantly interfered with.
This illustrates that the interference free performance of hoptoglobin detection kit of the invention is apparently higher than hoptoglobin on existing market and examines
The interference free performance of test agent box.
Correlation test:
Control test is carried out using the reagent of embodiment 1, embodiment 2, embodiment 3 and control group, while having detected 20
Clinical serum sample, testing result is as shown in table 4, and obtain the kit of embodiment 1-3 respectively with the kit of control group
Between correlation curve (as shown in Figs. 1-3).
4 correlation test result of table
Relative deviation (%)=(measurement mean value-control group measurement mean value of embodiment)/control group measurement mean value ×
100%.
The related coefficient of above-described embodiment 1,2 and the 3 pre- control groups of gained reagent is to be respectively it can be seen from table 4 and Fig. 1
0.9999,0.9999 and 0.9998, illustrate state common in hoptoglobin detection kit and existing market of the invention
The binding protein assay kit for certain company that food and medicine Surveillance Authority, family is approved has great correlation, of the invention
Certain that common State Food and Drug Administration is approved in the accuracy of hoptoglobin detection kit and existing market
The accuracy of the binding protein assay kit of company does not have notable difference, has further demonstrated that hoptoglobin inspection of the invention
The antibody of test agent box can effectively be combined with antigen, and the specificity of kit is stronger, can satisfy clinical needs.
Detection of Stability:
The reagent of embodiment 1, embodiment 2, embodiment 3 is uniformly distributed into 26 groups respectively, and obtains 26 groups of control groups
Reagent is as control.It is wherein placed into 2-8 DEG C of refrigerator for 13 groups, 13 groups are placed into 37 DEG C of water-baths, and the daily same time takes
Group reagent detection quality-control product (target value 1.52g/L) out, testing result is as shown in table 5, table 6, attached drawing 4 and attached drawing 5:
5 kit of table is placed on testing result after 2-8 DEG C of processing
Testing result after 37 DEG C of 6 kit of table processing
As can be seen from Table 5, after lasting 4 months, the reagent that the kit of embodiment 1 stores at 2-8 DEG C does not almost have
There is any decaying, the kit of embodiment 2 and embodiment 3 has a small amount of decaying, but is no more than 22%.But contrast agents are
Decay 11% at 30 days, has decayed 35% after 4 months.
As can be seen from Table 6, under the conditions of 37 degree, the kit of embodiment 1 is decayed when lasting 30 days after 7.9%, 4 months
Decay nearly 50%, the kit of embodiment 2 and embodiment 3 was decayed 54% left side of having decayed after 11% or so, 4 months at the 30th day
It is right.And contrast agents have just decayed when at the 9th day and decay 85% or so after 8.5%, 4 months.In conjunction with shown in Fig. 2, Fig. 3, say
Bright 1 reagent of embodiment HP detection kit more common than market under 2-8 DEG C and 37 DEG C of conditions of storage is more stable, but there are still
It is insufficient.
In conclusion the hoptoglobin detection kit of stabilization of the invention, high specificity have preferable repeatability,
Stability, specificity and anti-interference.
The above is a preferred embodiment of the present invention, it is noted that for those skilled in the art
For, without departing from the principles of the present invention, it can also make several improvements and retouch, these improvements and modifications
It should be regarded as protection scope of the present invention.
Claims (8)
1. the hoptoglobin detection kit of a kind of stabilization, high specificity, which is characterized in that including reagent R1 and reagent R2,
Wherein:
The ingredient and content of the reagent R1 is as follows:
The ingredient and content of the reagent R2 is as follows:
2. the hoptoglobin detection kit of stabilization according to claim 1, high specificity, which is characterized in that described
The ingredient and content of reagent R1 is as follows:
The ingredient and content of the reagent R2 is as follows:
3. the hoptoglobin detection kit of stabilization according to claim 1 or 2, high specificity, which is characterized in that institute
Stating buffer is one of PBS buffer solution, glycine buffer, Tris buffer or multiple combinations, the reagent R1 and examination
The temperature of buffer in agent R2 is 25 DEG C, pH value 7.4.
4. the hoptoglobin detection kit of stabilization according to claim 1 or 2, high specificity, which is characterized in that institute
Stating surfactant 1 is Triton X-100, and the surfactant 2 is polyoxyethylene laurel ether.
5. the hoptoglobin detection kit of stabilization according to claim 1 or 2, high specificity, which is characterized in that institute
Stating inorganic ion is one of sodium chloride, potassium chloride, magnesium chloride or multiple combinations.
6. the hoptoglobin detection kit of stabilization according to claim 1 or 2, high specificity, which is characterized in that institute
Stating accelerator is one of Polyethylene glycol-2000, polyethylene glycol-6000, polyethylene glycol-8 000 or multiple combinations.
7. the hoptoglobin detection kit of stabilization according to claim 1 or 2, high specificity, which is characterized in that institute
Stating preservative is PC-300.
8. the hoptoglobin detection kit of stabilization according to claim 1 or 2, high specificity, which is characterized in that institute
The ratio for stating reagent R1 and reagent R2 is 4:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910261110.6A CN110031631B (en) | 2019-04-02 | 2019-04-02 | Stable high-specificity haptoglobin detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910261110.6A CN110031631B (en) | 2019-04-02 | 2019-04-02 | Stable high-specificity haptoglobin detection kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110031631A true CN110031631A (en) | 2019-07-19 |
| CN110031631B CN110031631B (en) | 2021-04-23 |
Family
ID=67237186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910261110.6A Active CN110031631B (en) | 2019-04-02 | 2019-04-02 | Stable high-specificity haptoglobin detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110031631B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101726579A (en) * | 2008-10-17 | 2010-06-09 | 深圳迈瑞生物医疗电子股份有限公司 | Blood test reagent and method |
| CN102507957A (en) * | 2011-11-01 | 2012-06-20 | 北京利德曼生化股份有限公司 | Method and kit for determining apolipoprotein A2 by using immunity transmission turbidimetric method |
| CN103694970A (en) * | 2014-01-14 | 2014-04-02 | 河南金马石油科技有限责任公司 | Paraffin emulsion and preparation method thereof |
| CN104215632A (en) * | 2014-08-28 | 2014-12-17 | 宁波瑞源生物科技有限公司 | Stable lipase kit |
| CN105548573A (en) * | 2016-02-02 | 2016-05-04 | 潍坊三维生物工程集团有限公司 | Kit and method for detecting content of KAPPA light chain and application |
| CN106053444A (en) * | 2016-04-28 | 2016-10-26 | 安徽伊普诺康生物技术股份有限公司 | A kit for measuring a specific growth factor and a preparing method thereof |
| CN106053839A (en) * | 2016-07-12 | 2016-10-26 | 安徽伊普诺康生物技术股份有限公司 | Kit for determining haptoglobin and preparation method thereof |
-
2019
- 2019-04-02 CN CN201910261110.6A patent/CN110031631B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101726579A (en) * | 2008-10-17 | 2010-06-09 | 深圳迈瑞生物医疗电子股份有限公司 | Blood test reagent and method |
| CN102507957A (en) * | 2011-11-01 | 2012-06-20 | 北京利德曼生化股份有限公司 | Method and kit for determining apolipoprotein A2 by using immunity transmission turbidimetric method |
| CN103694970A (en) * | 2014-01-14 | 2014-04-02 | 河南金马石油科技有限责任公司 | Paraffin emulsion and preparation method thereof |
| CN104215632A (en) * | 2014-08-28 | 2014-12-17 | 宁波瑞源生物科技有限公司 | Stable lipase kit |
| CN105548573A (en) * | 2016-02-02 | 2016-05-04 | 潍坊三维生物工程集团有限公司 | Kit and method for detecting content of KAPPA light chain and application |
| CN106053444A (en) * | 2016-04-28 | 2016-10-26 | 安徽伊普诺康生物技术股份有限公司 | A kit for measuring a specific growth factor and a preparing method thereof |
| CN106053839A (en) * | 2016-07-12 | 2016-10-26 | 安徽伊普诺康生物技术股份有限公司 | Kit for determining haptoglobin and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110031631B (en) | 2021-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Frijhoff et al. | Clinical relevance of biomarkers of oxidative stress | |
| Miyata et al. | Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. | |
| KR100257733B1 (en) | Immunochemical detection of in vivo advanced glycosylation end products | |
| Franke et al. | Increased levels of advanced glycation end products in human cataractous lenses | |
| Feld et al. | Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment | |
| US7968279B2 (en) | Reference control for cell by cell analysis | |
| Nishad et al. | Advanced-glycation end-products induce podocyte injury and contribute to proteinuria | |
| CN106053839A (en) | Kit for determining haptoglobin and preparation method thereof | |
| US7361513B2 (en) | Cellular controls for glycated hemoglobin Hb A1c | |
| Glover | Retinol-binding proteins | |
| DK159174B (en) | PROCEDURE FOR DETERMINING DIRECT AND TOTAL CAR RUBIN AND ANY SUITABLE AGENT | |
| WO2020059563A1 (en) | Artificial feces, and method for managing accuracy of fecal occult blood test using same | |
| Rossi et al. | Membrane skeletal protein S-glutathionylation and hemolysis in human red blood cells | |
| CN110031631A (en) | Stablize, the hoptoglobin detection kit of high specificity | |
| Hoch et al. | Estimation of serum proteins | |
| CN109164259A (en) | A kind of hoptoglobin detection kit of high sensitivity | |
| CN112240931B (en) | Immunity turbidimetry kit | |
| US20210381935A1 (en) | Preservative solution for heme protein, and method for stabilizing heme protein | |
| Wu et al. | Glycosylation and binding of α-dicarbonyl compounds and human serum albumin based on spectral analysis and molecular simulation | |
| Yücel et al. | Evidence of increased oxidative stress by simple measurements in patients with dilated cardiomyopathy | |
| US4030885A (en) | Bilirubin determination | |
| SUZUKI et al. | Immunohistochemical staining of renal biopsy samples in patients with diabetic nephropathy in non‐insulin dependent diabetes mellitus using monoclonal antibody to advanced glycation end products | |
| Moore et al. | Changes in erythrocyte membranes during cold storage of whole blood | |
| Xie et al. | In vitro Glycation of Hemoglobin by Acetone and-hydroxibutirate | |
| CN107064527A (en) | A kind of seralbumin detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Stable and specific binding Globin detection kit Effective date of registration: 20230628 Granted publication date: 20210423 Pledgee: Bank of Communications Ltd. Shandong branch Pledgor: BIOBASE BIODUSTRY (SHANDONG) Co.,Ltd. Registration number: Y2023980045843 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210423 Pledgee: Bank of Communications Ltd. Shandong branch Pledgor: BIOBASE BIODUSTRY (SHANDONG) Co.,Ltd. Registration number: Y2023980045843 |